BioSpace News Archive

The diagnostics company SphingoTec GmbH, announces that, during the 4th Scientific Symposium held near Potsdam, Germany, international medical experts discussed the latest developments in diagnostic and therapeutic innovations for advancing precision medicine in critically ill patients.

eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors for the treatment of cancer, announced it has appointed Douglas Warner, M.D., as chief medical officer.

HUTCHMED and AstraZeneca announce that preliminary results from the SAVANNAH Phase II trial showed that TAGRISSO® plus savolitinib demonstrated an objective response rate of 49% in patients with epidermal growth factor receptor-mutated non-small cell lung cancer with high levels of mesenchymal epithelial transition overexpression and/or amplification, defined as IHC90+ and/or FISH10+, whose disease progressed on treatment with TAGRISSO®.

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, announced financial results for the second quarter of 2022 and provided a general business update.

Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today reported financial results for the second quarter ended June 30, 2022.

PDS Biotechnology Corporation will discuss its financial results for the quarter ended June 30, 2022 and provide a business update on its conference call today.

Compugen Ltd. announced today that the European Patent Office has granted Compugen a new patent covering anti-PVRIG antibodies for use in cancer treatment.

TAGRISSO® plus savolitinib demonstrated 49% objective response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial.

Stoke Therapeutics, Inc., a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, reported financial results for the second quarter of 2022 and provided business updates.

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the second quarter ended June 30, 2022 and provided a business update.